Top five ophthalmology news stories this week

This week, the most frequently viewed ophthalmology articles on Healio.com ranged from topics such as the OSN New York meeting to Genentech’s receipt of the U.S. Food and Drug Administration’s breakthrough therapy designation for Lucentis.

Here are the top five most-viewed stories from December 15^th to December 19^th:

1. Genentech receives FDA breakthrough therapy designation for Lucentis

The U.S. Food and Drug Administration has granted breakthrough therapy designation for Lucentis for the treatment of diabetic retinopathy, according to press release from Genentech. Read more.

2. Combination therapy may improve management of acute retinal necrosis

Patients treated with a combination systemic and intravitreal antiviral therapy for acute retinal necrosis may be more likely to have an improvement in visual acuity, avoid severe vision loss and have a decreased incidence of retinal detachment, according to study findings. Read more.

3. Video: Femtosecond cataract surgery — Real-time patient flow and logistics of laser and phacoemulsification

NEW YORK — John Berdahl, MD, discusses refractive laser-assisted cataract surgery from the patient perspective at OSN New York. Read more.

4. Treat-and-extend AMD regimen sustains outcomes for up to 3 years

A treat-and-extend protocol improved vision and reduced retinal thickness for up to 3 years in patients with neovascular age-related macular degeneration, according to study findings. Read more.

5. Actavis’ newly appointed senior management team to take effectafter Allergan acquisition

Actavis announced the company’s newly appointed management team will become effective immediately after the anticipated successful close of the Allergan acquisition in the second quarter of 2015, according to a press release. Read more.